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Clinical evidence of heart failure (HF) is a consistent and powerful predictor of outcome in patients after 
myocardial infarction (MI).1 HF after MI reflects elevated 
left ventricular (LV) filling pressures, which are frequently 
observed despite apparently minor myocardial damage, 
with little overall effect on LV ejection fraction (LVEF). 
The pathophysiological mechanisms are incompletely 
understood but involve impaired relaxation and decreased 
LV chamber compliance, hence, abnormalities in diastolic 
function. Observational studies suggest that patients with 
preserved LVEF and diastolic dysfunction post MI has 
a worse prognosis than patients with infarcts of similar 
size but no diastolic dysfunction.2 Abnormal LV diastolic 
function is characterized by a disproportionate increase in 
filling pressure with exercise,3–5 especially when chamber 
compliance is decreased. In case of increased LV filling 
pressures, left atrial (LA) pressure is elevated, exposing 
the pulmonary vascular bed to the increased pressure. In 
accordance, pulmonary arterial pressure (PAP) is frequently 
increased after MI,4 and also associated with increased 
mortality and morbidity after MI, independent of LVEF.2 
Although there are robust data to support specific therapies 
for systolic dysfunction after MI,6 the optimal management 
of patients with presumed diastolic dysfunction and 
especially those with preserved LVEF is unknown. Because 
hemodynamic abnormalities caused by diastolic dysfunction 
Background—Diastolic dysfunction is frequently seen after myocardial infarction and is characterized by a disproportionate 
increase in filling pressure during exercise to maintain stroke volume. We hypothesized that sildenafil would reduce 
filling pressure during exercise in patients with diastolic dysfunction after myocardial infarction.
Methods and Results—Seventy patients with diastolic dysfunction and near normal left ventricular ejection fraction 
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9 weeks there were no differences in pulmonary capillary wedge pressure at rest (13±4 versus 13±3 mm Hg, P=0.25) or 
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are believed to drive the progression from an asymptomatic 
stage to symptomatic heart failure, therapies that lower LV 
filling pressure or increase LV chamber compliance might 
attenuate this evolution and reduce the incidence of overt 
heart failure after MI.
Clinical Perspective on p 1208
Sildenafil is a potent and selective phosphodiesterase-5 
(PDE-5) inhibitor that suppresses degradation of cyclic 
guanosine monophosphate. Sildenafil attenuates myocar-
dial maladaptive remodelling in pressure overload states,7,8 
improves endothelium dependent vasodilation,9,10 and has 
positive hemodynamic effects without causing systemic 
hypotension in a wide variety of patient populations.8,10–15 
These effects could likely be beneficial after MI, and thus we 
hypothesized that PDE-5 inhibition would improve central 
hemodynamics (reduce pulmonary capillary wedge pressure 
[PCWP]), increase cardiac index (CI), and reduce PAP at 
rest and during exercise in patients with diastolic dysfunc-
tion after MI.
Methods
Study Design
In a randomized, double-blind, placebo-controlled study, male or non-
pregnant females aged ≥50 years with a recent documented MI, dia-
stolic dysfunction, and LVEF ≥45% on echocardiography performed 
within 48 hours of the MI were enrolled. Diastolic dysfunction was 
defined as the ratio of early diastolic peak mitral inflow velocity (E) 
to early mitral annulus diastolic velocity (e’) ratio > 8 and at least 
moderate LA dilatation (LA volume index>34 mL/m2).16,17 Patients 
with permanent atrial fibrillation, known history of cardiomyopa-
thy, more than mild valvular heart disease, obstructive or restric-
tive pulmonary disease, inability to perform exercise testing, and 
those with inadequate acoustic windows were excluded (Figure 1). 
As part of standard management of MI an urgent coronary angiogram 
was performed in all patients, which was performed before echocar-
diography in all patients. Revascularization was performed at the dis-
cretion of the attending invasive cardiologist. Patients with residual 
stenosis >60% in any epicardial coronary arteries and those referred 
for coronary bypass surgery were not eligible.
Subjects were randomized in a 1:1 double-blind fashion to 
 receive sildenafil or matching placebo using a computer-generated 
randomization schedule prepared before study start. Compliance 
was assessed by pill count, and adequate compliance was defined 
as adherence to medication >80%.18 The ethics Committee for the 
Capital Region Copenhagen approved the trial protocol (ID: H-A-
2009-023). All patients provided written informed consent, and the 
study was registered with ClinicalTrials.gov (ID: NCT 01046838). 
The study was conducted in accordance with the International 
Conference on Harmonization Guidelines for Good Clinical Practice 
and the Declaration of Helsinki and was monitored externally by the 
Copenhagen GCP unit.
Before randomization (baseline), spirometry, blood testing, com-
prehensive resting Doppler echocardiography, resting right heart 
catheterization, 6-minute walk test, and symptom-limited supine cy-
cle exercise test with simultaneous echocardiography and right heart 
catheterization were performed. Estimated glomerular filtration rate 
was calculated according to the Modification of Diet in Renal Disease 
formula.19 After randomization subjects were given 20 mg sildenafil 
thrice daily or matching placebo. After 1 week of treatment, the dose 
of sildenafil was increased to the target dose of 40 mg thrice daily or 
matching placebo. After 9 weeks treatment, echocardiography, right 
heart catheterization, and exercise test were repeated.
Echocardiography
Resting and exercise echocardiography was performed by an expe-
rienced echocardiographer using a Philips iE33 (Philips Healthcare, 
Best, The Netherlands) cardiac ultrasound system. Images were 
stored digitally for offline analysis using Philips Xcelera analysis 
software version 3.1 (Philips Healthcare). LV volumes and LVEF 
were assessed using the Simpson modified rule from the apical 4 and 
2 chamber views. LA maximal volume was estimated from the api-
cal 4- and 2-chamber views using the area length method. Mitral in-
flow was assessed in the apical 4-chamber view with the pulsed wave 
Doppler sample volume placed at the tips of mitral leaflets during 
diastole. From the inflow, peak E wave velocity was measured. Mitral 
annular motion was assessed using pulsed wave tissue Doppler with 
the sample volume placed in the septal and lateral mitral annulus. The 
mean of the septal and lateral e´ velocity was used for calculation of 
E/e´. Wall motion scores were assessed semiquantitatively using the 
standard 16 segmental model in accordance with current guidelines.16 
For Doppler recordings the average of 3 to 5 consecutive beats were 
measured using a horizontal sweep of 75 to 100 cm/s. The analy-
ses were performed blinded to allocated treatment and to invasive 
measurements.
Figure 1. Consort diagram depicting the flow of 
participants through the Sildenafil and Diastolic 
Dysfunction After Acute Myocardial Infarction 
(SIDAMI) trial. LA indicates left atrial; LVEF, left ven-
tricular ejection fraction; MI, myocardial infarction; 
and IQR, interquartile range. 
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Invasive Hemodynamic Measurements
Right heart catheterization was performed using a standard 7.5-F triple 
lumen Swan-Ganz thermistor and balloon-tipped catheter (Edwards 
Lifesciences, Irvine, CA). The catheter was introduced guided by 
ultrasound under local anesthesia using the Seldinger technique 
into the right internal jugular vein and advanced to the pulmonary 
artery. PCWP, right atrial pressure (RAP), systolic PAP, diastolic 
PAP, mean PAP, and cardiac output were measured at each level of 
exercise until exhaustion and after 5 minutes of rest. PCWP at rest 
and post exercise was measured at end-expiration. During exercise 
PCWP was averaged over 10 seconds. Cardiac output was measured 
using thermodilution as the average of 3 measurements with ≤10% 
variance. The pressure difference between LV diastolic pressure 
and pericardial pressure (transmural filling pressure) was estimated 
as the difference between PCWP and RAP.20–22 Cardiac output and 
stroke volume (SV) were indexed to body surface area as CI and 
stroke volume index (SVI). Pulmonary vascular resistance index was 
calculated as follows: 80×(mean PAP−PCWP)/CI. Systemic vascular 
resistance index was calculated as follows: 80×(mean arterial 
pressure [MAP]−RAP)/CI. LV stroke Work Index was calculated 
as SVI×(MAP−PCWP)×0.0136. At rest and at maximal exercise a 
central venous blood sample was drawn from the pulmonary artery 
and analyzed for lactate concentration, mixed venous oxygen 
saturation and pH. Arterial and venous oxygen content was calculated 
as follows: Hemoglobin (g/dL)×1.34(mlO2/g hemoglobin)×SatO2. 
Arterio-venous difference (a-vO2) was calculated as arterial oxygen 
content – venous oxygen content.
Exercise Protocol
All patients performed a multistage symptom-limited supine cycle 
ergometer exercise test using an Echo Cardiac Stress Table (Lode 
B.V., The Netherlands). Workload started at 0 watt and increased 
by 25 watts every 2 minutes. Patients were encouraged to exercise 
until exhaustion (Borg>18).23 Brachial blood pressure was mea-
sured by sphygmomanometry at baseline and at every 2 minutes 
until maximum workload was reached and repeated after 5 minutes 
of rest.
End Points
The primary end points were resting and peak exercise PCWP after 
9 weeks treatment. Secondary end points were resting and peak exer-
cise CI and PAP after 9 weeks of treatment.
Statistical Analysis
No reference data exist on pulmonary artery pressure or pulmonary 
capillary wedge pressure at exercise in a similar population. The 
sample size was therefore determined based on E/e’. With a standard 
deviation in E/e’ of 5,24 alpha = 0.05 and beta = 0.80, a sample size 
of 60 patients allowed for the detection of a difference in E/e’ of 3.6. 
After enrollment of 10 patients confirmatory sample-size estimation 
was performed based on PCWP. In this group peak-exercise PCWP 
was 35±5 mm Hg. Based on these conservative cross sectional, 60 
patients were needed to detect a true difference in PCWP of 4 mm Hg 
with a power of 0.8, which was considered clinically relevant. To ac-
count for dropouts and noncompliance a sample size of 70 patients 
was enrolled.
Data are presented as mean±SD or median (interquartile range) 
unless otherwise indicated. Normally distributed within-individual 
changes from baseline to follow-up were evaluated using the paired 
t test. Between-group differences from baseline to follow-up were 
evaluated using both a standard t test and a general linear model with 
treatment as fixed effect and baseline value as a covariate to adjust 
for small differences between groups at baseline due to small sample 
size. Estimated differences between groups are presented with 95% 
confidence limits (CL). For non-Gaussian distributed variables non-
parametric rank sum test was used. Intention-to-treat analysis was 
performed for all variables. A probability value <0.05 was considered 
significant. Statistical analyses were performed using SAS version 
9.2 (Cary, NC).
Results
Seventy patients were randomized 32 (interquartile range, 
23–43) days after admission for MI (Figure 1); 35 patients 
were randomized to receive sildenafil and 35 to receive pla-
cebo. Baseline characteristics for both groups are presented 
in Table 1. All subjects were on stable medications and free 
of angina, and were in New York Heart Association class I or 
II. At follow-up concomitant pharmacological treatment was 
unchanged in all but 4 patients in the placebo and 2 in the 
sildenafil group. In the sildenafil group 1 patient discontinued 
low-dose β-blocker treatment, and in both groups 1 patient 
discontinued ACE and calcium inhibitors due to presumed 
Table 1. Baseline Demographic and Clinical Characteristics 
and Cardiovascular Parameters in the Placebo and Sildenafil 
Groups
Placebo Sildenafil
Age, y 62±7 63±8
Time from MI to  
randomization, d (IQR)
31 (22–42) 33 (23–43)
Male, n (%) 30 (86%) 31 (89%)
BMI, kg/m2 28±5 27±4
BSA, m2 2.1±0.2 2.0±0.2
Current smokers, n (%) 11 (31%) 7 (20%)
Hypertension, n (%) 15 (43%) 18 (51%)
Diabetes mellitus, n (%) 3 (9%) 3 (9%)
Drug therapy
Diuretics, n (%) 2 (6%) 3 (9%)
β-Blockers, n (%) 34 (97%) 27 (77%)
ACEI/ARB, n (%) 14 (40%) 9 (26%)
CA2+ blockers, n (%) 5 (14%) 8 (23%)
Statins, n (%) 35 (100%) 35 (100%)
STEMI, n (%) 30 (86%) 30 (86%)
RCA culprit, n (%) 14 (40%) 20 (57%)
LCX culprit, n (%) 7 (20%) 5 (14%)
LAD culprit, n (%) 14 (40%) 10 (28%)
Multi vessel disease, (%) 3 (9%) 7 (20%)
Max TnT, µg/L, median (IQR) 1280 (620–6000) 2680 (1250–5780)
FEV1 (l/min) 3.0±0.7 3.0±0.6
FEV1 (% of expected) 89±14 96±16
TAPSE, cm 2.6±0.4 2.6±0.4
E/A ratio 1.1±0.4 1.1±0.4
E/e’ 10.8±2.6 11.2±2.7
Data are presented as mean±SD, n (%) unless otherwise indicated. ACEI 
indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor 
blockers; BMI, body mass index; BSA, body surface area; E/A, ratio between 
early (E) and late (A) transmitral filling velocity; E/e′, ratio between early (E) 
transmitral filling velocity and early diastolic tissue Doppler velocity (e′); FEV1, 
forced expiratory volume; IQR, interquartile range; LAD, left anterior descendent 
coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; 
STEMI, ST-elevation myocardial infarction; TAPSE, tricuspid annular plane 
systolic excursion; and TnT, Troponin-T.
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side effects. In the sildenafil group 1 patient initiated ACE 
inhibitor treatment, and in the placebo group 1 initiated diuret-
ics and 1 patient initiated a calcium channel inhibitor.
Resting Hemodynamic Variables
Primary End Point
At baseline, resting central hemodynamic values were sim-
ilar in the sildenafil and the placebo group (Table 2). After 
9 weeks of treatment, there were no significant differences 
within or between group changes in resting unadjusted 
PCWP (−0.6±4.1 versus +0.6±3.6 mm Hg, P=0.25; Figure 2, 
placebo and sildenafil, respectively) or after adjustment of 
prerandomization PCWP (−0.5 mm Hg; 95% CL, −2.2 to +1.2 
mm Hg; P=0.56).
Secondary End Points
From baseline to follow-up there was a significant increase in 
CI in the sildenafil group compared with placebo (+0.2±0.4 
versus -0.1±0.5 L/min/m2, P=0.02; Figure 3). CI remained 
higher in the sildenafil group after adjustment of prerandom-
ization CI (+0.2 L/min/m2; 95% CL, +0.1 to +0.4 L/min/m2; 
P=0.006). There were no significant differences within or 
between groups in resting unadjusted or adjusted mean PAP or 
pulmonary vascular resistance index. Diastolic blood pressure 
(P=0.02), MAP (P=0.05), and systemic vascular resistance 
Table 2. Exercise-Induced Changes in Invasive Hemodynamics and LV Volumes From Rest to Peak Exercise at Baseline
Placebo Sildenafil
Baseline Follow-Up Baseline Follow-Up
Rest Peak Exercise Rest Peak Exercise Rest Peak Exercise Rest Peak Exercise
HR 62±11 124±16 59±9 119±18 61±10 124±17 59±9 123±17
Systolic BP, mm Hg 136±23 195±28 136±17 188±32 137±16 182±22 131±17 180±27
Diastolic BP, mm Hg 76±13 95±21 77±11 96±23 76±10 93±14 72±8*† 83±15*†
MAP, mm Hg 90±14 117±18 92±11 114±23 90±9 113±12 86±9*† 104±15†
CI, L/min/m2 2.7±0.7 7.5±1.5 2.6±0.4 7.0±1.3 2.6±0.6 7.5±1.5 2.8±0.5*† 7.8±1.4*
RAP, mm Hg 7±2 15±6 8±3 15±6 6±3 12±5 7±2 12±6
sPAP, mm Hg 27±6 62±12 28±6 63±13 26±5 57±13 26±6 58±13
dPAP, mm Hg 15±4 37±9 15±4 38±8 14±4 34±8 15±4 34±10
mPAP, mm Hg 20±5 49±10 21±4 50±8 19±5 44±9 20±4 44±10
PCWP, mm Hg 13±3 35±8 13±4 35±8 12±4 31±7 13±3 31±8
TMP, mm Hg 6±3 20±7 6±3 20±8 6±3 19±5 6±3 18±4
Watts 126±31 137±37 134±42 135±37
pH, mixed venous 7.40±0.02 7.23±0.07 7.40±0.02 7.23±0.06 7.41±0.02 7.25±0.06 7.41±0.02 7.24±0.06
SVO
2, % 70±4 34±9 70±4 34±12 70±4† 38±14 71±5† 37±13
a-v0
2 difference, mL/dL 5.02±0.66 12.44±1.91 5.16±0.75 12.51±2.50 4.94±0.83 11.52±2.66 4.75±0.71* 11.86±2.60
Lactate, mmol/l 0.96±0.43 8.10±2.94 0.88±0.25 7.95±2.83 0.86±0.34 8.09±3.07 0.91±0.45 7.73±2.67
SVRI, dynes.m2/sec.cm-5 2633±801 1165±324 2660±587 1222±336 2646±552 1101±278 2269±467*† 993±181*
PVRI, dynes.m2/sec.cm-5 220±77 157±66 229±82 174±75 207±71 135±61 192±74 142±52
LVEDV Indexed, ml/m2 64±13 62±13 65±15 60±14 60±9 60±11 66±10† 59±11
LVESV Indexed, ml/m2 28±8 24±8 27±9. 22.5±9.5 27±5 24±7 27±8 23±8
SV Indexed, ml/m2 36±7 38±8 38±9 37±10 33±7 36±6 39±8† 36±9
LVEF, % 56±7 61±7 59±8 63±10 55±6 59±7 60±9† 62±11
WMS 1.3±0.2 - 1.2±0.2 - 1.3±0.2 - 1.2±0.2 -
LA volume index, ml/m2 44±11 - 49±11 - 43±11 - 49±10† -
LV mass index, g/m2 93±20 - 91±18 - 93±19 - 95±20 -
LVSWI, gm-m/beat 37.7±10.5 41.8±13.0 41.4±11.7 40.5±16.0 35.2±9.6 40.8±9.4 38.9±10.3 35.2±12.0
6 MWT, m 558±72 - 589±73† - 568±77 - 589±83† -
Nt-Pro-BNP, pg/L Median (IQR) 408 (236–846) - 290 (140–363)† - 576 (298–833) - 293 (185–404)† -
eGFR, ml/ m2/min 89±17 - 91±17 - 92±21 - 94±22 -
Data are presented as mean±SD. For between-group comparisons: *P<0.05 sildenafil and placebo adjusted. For within group comparisons: † P<0.05; 6 MWT, 
6-minute walk distance. BP indicates blood pressure; CI, cardiac index; dPAP, diastolic pulmonary arterial pressure; eGFR, estimated glomerular filtration rate; HR, 
heart rate; IQR, interquartile range; LA, left atrial; LV, left ventricular; LVEDV, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, 
left ventricular end-systolic volume index; LVSWI, left ventricular stroke work index; MAP, mean artery pressure; mPAP, mean pulmonary arterial pressure; NT-ProBNP, 
N-terminal probrain natriuretic peptide; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVRI, pulmonary vascular resistance index; 
RAP, right atrial pressure; sPAP, systolic pulmonary arterial pressure; SV, stroke volume derived from echocardiography; SVO2, mixed venous oxygen saturation; SVRI, 
systemic vascular resistance index; TMP, left ventricular transmural filling pressure; and WMS, wall motion score.
There were no differences between resting baseline values for placebo and sildenafil, all P>0.05.
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index (P=0.005) were lower in the sildenafil group compared 
with placebo. This result did not change when adjusting for 
baseline values; the estimated mean difference was signifi-
cantly lower for diastolic blood pressure (−6 mm Hg; 95% CL, 
−9 to −2 mm Hg; P=0.005), MAP (−5 mm Hg; 95% CL, −10 
to −1 mm Hg; P=0.01), and systemic vascular resistance index 
(−390 dynes.m2/sec.cm−5; 95% CL, −589 to −192 dynes.m2/
sec.cm−5; P=0.0002). Left ventricular end-diastolic volume 
index (LVEDVI) increased mean +6 mL/m2 (95% CL, +3 to 
+10 mL/m2, P=0.001) within the sildenafil group whereas 
LVEDVI did not change within the placebo group (+0 mL/m2; 
95% CL, −4 to +4 mL/m2, P=0.92, Figure 4). As a consequence 
of the different effect of sildenafil on LVEDVI there was a sig-
nificant increase in SVI in the sildenafil group after 9 weeks of 
treatment when measured both by echocardiography (+6 mL/
m2; 95% CL, +3 to +9 mL/m2; P=0.0005) and by thermodilu-
tion (+4 mL/m2; 95% CL, +2 to +7 mL/m2; P=0.0006). This 
enhancement in stroke volume and cardiac output with silde-
nafil coupled with a reduction in a-vO2 difference compared 
with placebo between groups (4.75±0.71 versus 5.16±0.75 
mL/100mL, P=0.03). There were no within- or between group 
differences in RAP, N-terminal probrain natriuretic peptide or 
estimated glomerular filtration rate, right ventricular function 
(TAPSE), E/e´, LV mass, E -, A – velocities, or E deceleration 
time after 9 weeks of treatment (Table 2).
Exercise Hemodynamic Variables
With exercise all subjects reached the anaerobic threshold as 
evidenced by significant increase in mixed venous blood lac-
tate and significant drop in pH with no between-group dif-
ferences (Table 2). There was no difference between groups 
in achieved watts during exercise at baseline (P=0.42) or at 
follow-up (P=0.84).
Primary End Point
Both groups experienced a substantial and abnormal increase 
in PCWP and PAP with exercise (Table 2). After 9 weeks of 
treatment, there was a trend for higher peak PCWP in the 
placebo group compared with sildenafil (35±8 mm Hg versus 
31±7 mm Hg, P=0.07). However, after adjusting for baseline 
values the estimated difference in PCWP between groups was 
only mean +1 mm Hg higher in the placebo group (95% CL, 
−2 to +5 mm Hg; P=0.39; Figure 2).
Secondary End Points
The change in peak exercise CI from baseline to 9 weeks was 
significantly higher in the sildenafil compared with placebo 
group (+0.2±1.1 versus -0.4±1.3 L/min/m2, P=0.05) also 
when adjusting for baseline (+0.7 L/min/m2; 95% CL, +0.1 
to +1.2 L/min/m2; P=0.02; Figure 5). There were no signifi-
cant differences within or between-groups in heart rate (−3 
bpm; 95% CL, −9 to +3 bpm; P=0.28), mean PAP (+0 mm Hg, 
Figure 2. Pulmonary capillary wedge pressure 
(PCWP) at rest and peak exercise from baseline 
to follow-up for placebo (dashed line and circle) 
and sildenafil (solid line and square). The error bars 
represent standard deviation. Statistical evaluations 
were performed using ANCOVA.
Figure 3. Cardiac index (CI) at rest from baseline 
to follow-up for placebo (dashed line and circle) 
and sildenafil (solid line and square). The error bars 
represent standard deviation. Statistical evaluations 
were performed using Student t test and ANCOVA.
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95% CL, −4 to +3; P=0.85), or pulmonary vascular resistance 
index (+13 dynes.m2/sec.cm-5; 95% CL, −17 to +43 dynes.m2/
sec.cm-5, P=0.38) placebo and sildenafil, respectively.
Estimated difference in exercise diastolic blood pressure 
(−13 mm Hg, 95% CL, −23 to −2 mm Hg, P=0.02), and 
estimated difference in systemic vascular resistance index 
(−205 dynes.m2/sec.cm−5, 95% CL, −349 to −60 dynes.m2/
sec.cm−5, P=0.007) were lower in the sildenafil group 
compared with the placebo group when adjusting for baseline 
values. At peak exercise there was no significant within- or 
between-group differences in LVEDVI (adjusted P=0.68, 
unadjusted P=0.93).
Adverse Events and Compliance
During treatment no serious adverse events or deaths occurred. 
Fourteen adverse events with possible relation to sildenafil 
were reported during the study period (n=12 for the sildenafil 
group, and n=2 for the placebo group, P=0.006; Table 3). 
Adverse events were generally mild and transient, and most 
resolved spontaneously. In 2 patients with dyspepsia a proton 
pump inhibitor was prescribed. One patient in the sildenafil 
group discontinued medication as a result of dyspnea, and 
1 had the dose reduced to 20 mg thrice daily also as a result of 
dyspnea. In the placebo group 1 patient withdrew consent and 
another patient emigrated. Compliance by pill count was good; 
58 (87%) of the 67 who completed the study were compliant.
Discussion
The Sildenafil and Diastolic Dysfunction After Acute 
Myocardial Infarction (SIDAMI) trial is to our knowledge 
the largest randomized, double-blind, placebo-controlled 
trial to invasively and echocardiographically investigate the 
Figure 4. Relationship between left ventricular 
end-diastolic volume index (LVEDVI; x axis) and 
pulmonary capillary wedge pressure (PCWP; y axis) 
in sildenafil (square) and placebo (circle) at baseline 
(empty legends) and at follow-up (solid legends). 
Error bars represent standard error of the mean. 
Statistical evaluations were performed using  
paired t test.
Figure 5. Cardiac index (CI) at peak exercise from 
baseline to follow-up for placebo (dashed line and 
circle) and sildenafil (solid line and square). The 
error bars represent standard deviation. Statistical 
evaluations were performed using Student t test 
and ANCOVA.
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hemodynamic response at rest and during exercise to PDE-5 
inhibition, and the first study of PDE-5 inhibition in patients 
with preserved LVEF, diastolic dysfunction, and exercise-
induced pulmonary venous hypertension post MI. Sildenafil did 
not lower LV filling pressure at rest or during exercise (primary 
end point). However, sildenafil treatment was associated with 
some beneficial hemodynamic effects, including increases in 
stroke volume, cardiac output, and reductions in LV afterload. 
These positive effects of PDE-5 inhibition observed in this trial 
must be interpreted as hypothesis-generating, but suggest that 
further studies evaluating the use of this class of medication in 
the post MI setting are warranted.
Despite the marked increase in LV filling pressure with 
exercise and contrary to our primary hypothesis, sildenafil did 
not lower LV filling pressure. The study was initially pow-
ered to detect a reduction of PCWP of ≈4 mm Hg. With the 
characteristics of the final study population a difference in 
PCWP of 5 mm Hg would be detectable with power of 80% 
and alpha=0.05, corresponding to a ≈15% decrease of peak 
exercise PCWP. Thus the lack of effect on the primary end 
point is unlikely a result of inadequate power. The reason 
for the absence of effect on primary end point is unclear, but 
we speculate that this could be attributable to the relatively 
normal pulmonary vascular resistances noted in the current 
study. Despite severe elevations in pulmonary artery pressures 
with exercise, PVR was remarkably normal at rest and during 
exercise, in contrast with the reductions in systemic vascular 
resistance by sildenafil. Previous studies have demonstrated 
that PDE-5 is significantly more upregulated in the setting of 
heart failure with pulmonary vascular disease with high PVR 
as compared with normal pulmonary vasculature.25 This could 
possibly also explain the apparently opposed results of the 
present study with a recent study by Guazzi et al.14 In that 
study impressive improvements in pulmonary arterial pres-
sure, RV function and dimension, LV size, and distensibility 
was observed after 12 months treatment with sildenafil in a 
group of patients with HFpEF. Opposed to the present study 
their patients were characterized by severe RV dysfunction 
and increased pulmonary vascular resistance. In addition to 
PDE-5 upregulation, an explanation may be that these patients 
with diastolic dysfunction are conditioned to tolerate a high 
LV filling pressure with exercise and thus will not stop exer-
cising until this filling pressure is reached. This is supported 
by the low variability between baseline and follow-up in peak 
exercise PCWP observed in both groups. Finally, we cannot 
exclude the possibility that our sensitivity to detect PCWP 
effects of sildenafil might have been attenuated by performing 
exercise studies in the supine position, where venous return 
and preload is highest, although we have previously validated 
the method in MI patients with and without diastolic dysfunc-
tion and healthy controls.4
In agreement with the observed changes in PCWP we did 
not detect any significant improvement in diastolic function 
as assessed by Doppler echocardiography. However, these 
negative results do not entirely preclude a subtle effect on 
diastolic function, as the sildenafil group was able to increase 
their peak cardiac output >1 L/min compared with placebo 
without an increase in LV filling pressure. In addition, the 
observed increase in LVEDVI at an unchanged PCWP could 
suggest an increase in LV chamber compliance or capacitance 
(myocardial effect), as has recently been demonstrated in 
heart failure animal models with PDE-5 inhibition.26
Though filling pressure was unaffected we did observe an 
increase in cardiac output at rest and during exercise with 
sildenafil. This increase in CI was consistently observed using 
echocardiography, thermodilution, and indirectly by measur-
ing a-v O2 difference supporting a genuine effect of sildenafil. 
This increase in cardiac output could be attributable to a vas-
cular effect of PDE-5 inhibition with vasodilation as a result 
of improved endothelial function.9,10,27,28 The improvement in 
cardiac output is in agreement with previous smaller studies 
in patients with HFpEF,14 HFrEF,13,29,30 aortic stenosis,8 and 
in animal models of severe pressure overload.10,12,31 However, 
if the vascular effect were the only mechanism, a reduction 
in LVESVI would also have been anticipated. Therefore, the 
unexpected increase in LVEDVI with an unchanged LVESVI 
is unlikely alone a result of reduced afterload. Post-MI 
adverse remodeling with altered geometry and progressive LV 
dilatation is unequivocally a negative prognostic sign, where 
the increase in end-systolic and end-diastolic volumes occurs 
to maintain an adequate cardiac output to meet the metabolic 
demand and is closely associated with neurohormonal acti-
vation.6,32 Usually adverse remodeling is seen in patients that 
have sustained large MI with marked depression of LVEF. 
This is a different population compared with the present 
study population, and we speculate that the slight increase 
in LVEDVI in the current study is not reflective of a nega-
tive effect on remodeling, but rather an enhancement in dia-
stolic capacitance. A similar increase in end-diastolic volume 
has been demonstrated in HFpEF patients without MI14 and 
in animal heart failure models with sildenafil.26 Also, PDE-5 
inhibition has been shown to be cardioprotective in ischemic 
models33 and to attenuate maladaptive adrenergic stimula-
tion,34 processes which are thought to play key roles in the neu-
rohormonal activation and eccentric remodeling after larger 
infarcts. Furthermore, we observed a significant decrease in 
N-terminal probrain natriuretic peptide in both groups after 
9 weeks of treatment, all of which indicate that the observed 
increase in LVEDVI may not have been harmful. Larger stud-
ies of effects of PDE-5 Inhibition in HFpEF ongoing where 
ventricular geometry and exercise capacity will be evaluated 
in detail (RELAX Clinicaltrials.gov:NCT00763867).35
Limitations
Patients in the SIDAMI trial were required to undergo 2 car-
diopulmonary exercise tests with simultaneous right heart 
catheterization and echocardiography, which may intro-
duce selection bias for less symptomatic, more fit, and more 
Table 3. Adverse Events
Adverse Effects Placebo Sildenafil
Dyspepsia, n (%) 0 (0%) 6 (17%)
Headache and dyspepsia, n (%) 0 (0%) 2 (9%)
Headache alone, n (%) 1 (3%) 2 (6%)
Dyspnea, n (%) 0 (0%) 2 (6%)
Skin irritation, n (%) 1 (3%) 0 (0%)
Data are presented as number of patients (%).
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determined patients. Although the enrolled population did 
show extensive elevation in filling pressure with exercise, it 
is uncertain how the results might differ in more frail or more 
symptomatic patients. Subjects were studied during supine 
exercise, and results may differ with exercise performed in the 
upright position.
Although we found an acceptable compliance (>80% good 
compliance), an even better compliance could possibly have 
been achieved using a slow release tablet that could be admin-
istered once a day instead of 3 times a day. An improved 
compliance could possibly have augmented the results. The 
duration of the study was based on time to remodeling in 
previous MI studies,36 and it is possible that longer treatment 
duration could have augmented the possible myocardial and 
vascular effects. The initiation of the study was delayed to at 
least 2 weeks post MI to minimize the risk of complications 
from femoral angiographic access site and to allow initiation 
and up-titration of concomitant medication. Exercise capacity 
was assessed using achieved watts and 6-minute walk test, 
which clearly is less optimal than measurement of peak oxy-
gen consumption. However, adding expired gas analysis to 
the simultaneous right heart catheterization and echocardiog-
raphy during maximum supine exercise was not considered 
feasible.
Conclusion
Treatment with oral sildenafil is safe and well tolerated in 
patients with a recent MI and diastolic dysfunction. Despite 
marked increase filling pressure and pulmonary artery pres-
sure with exercise in this population, this was not affected by 
sildenafil, thus the primary end point was not met. Sildenafil 
did however suggest increased cardiac output and reduced 
systemic resistance at a constant filling pressure. Although 
these results must be considered as hypothesis-generating 
only, the signal of possible enhancement in LV compliance 
with PDE-5 inhibition may merit further prospective studies 
in patients with diastolic dysfunction.
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CLINICAL PERSPECTIVE
Multiple observational studies suggest that patients with preserved systolic function and diastolic dysfunction post myocardial 
infarction have a worse prognosis than patients with infarcts of similar size but no diastolic dysfunction. In addition, the 
optimal management of these patients is unknown. This group of patients is characterized by an abnormal hemodynamic 
response to exercise with an abnormal increase in filling pressure and pulmonary artery pressure. The raised filling pressure 
during exercise could be a marker of increased risk of progression to overt heart failure, which possibly could be modulated 
by the selective phosphodiesterase-5 inhibitor sildenafil. Accordingly, we performed a double-blind, randomized, placebo-
controlled trial in 70 patients with diastolic dysfunction and preserved systolic function after a myocardial infraction. All 
patients underwent supine exercise testing with simultaneous echocardiography and right heart catheterization to determine 
whether sildenafil 40 mg thrice daily over 9 weeks lowered pulmonary capillary wedge pressure (primary end point) or 
improved cardiac index and pulmonary arterial pressure (secondary end points) at rest and at peak exercise compared with 
matching placebo. After 9 weeks of treatment, sildenafil did not lower the primary end point (pulmonary capillary wedge 
pressure). Sildenafil did, however, increase cardiac output and reduce systemic resistance at a constant filling pressure. 
Although these results must be considered as hypothesis-generating only, the observed possible enhancement in LV 
compliance with PDE-5 inhibition merit further prospective studies in patients with diastolic dysfunction after myocardial 
infarction.
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